Pan-genotypic regimen for HCV effective in eight weeks for the majority of patients1
1. Puoti M. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: an integrated analysis of HCV genotype 1–6 patients without cirrhosis. J Hepatol. 2018 Aug;69(2):293-300
Method of administration
Dosage
Dosage plan for MAVIRET1
Reference the most recent version of the SmPC, scanning the QR Code.
The continually updated version of the SmPC is also available on the website https://rcpabbvie.it/mav
Ex-factory price (VAT EXCLUDED): € 14,000
Retail price (VAT EXCLUDED): € 23,105.60
Reimbursement class: A
Classification for supply: medicinal products subject to limited medical prescription, with single refills, sold to the public by prescription from hospital centers or specialists: infectious disease specialists, gastroenterologists, internists (RNRL)
Stored at AIFA on 09/25/2019 - Code IT-MAVI-190076
Translated from the Italian local content. Global approved content coming soon.
Bibliography:
1. MAVIRET, Summary of Product Characteristics